Edward Nash
Physical Medicine & Rehabilitation · The Woodlands, TXNPI 1962428656
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 306 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 46 manufacturers reported payments, led by AbbVie at 31.3% of the total. Among physical medicine & rehabilitation clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 306 payments — averaging $19.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Collegium Pharmaceutical, Inc.$473
- Pfizer$463
- Eisai Inc.$244
- Lilly USA, LLC$216
- MDD US Operations, LLC$175
- plus $2K from 40 others
What the payments were for
- Food & beverage$5,899100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Proclaim IPG$145
- QULIPTA$124
- UBRELVY$124
How this compares
$5,899 in reported general payments places this provider in the 90th percentile of 651 physical medicine & rehabilitation providers in Texas.
See all physical medicine & rehabilitation providers in Texas →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxycontinOxycodone Hcl | 15 | $23,866 |
| BelbucaBuprenorphine Hcl | 24 | $22,361 |
| Xtampza ErOxycodone Myristate | 43 | $22,246 |
| MounjaroTirzepatide | 13 | $16,011 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 402 | $12,291 |
| OzempicSemaglutide | 11 | $10,578 |
| Ambien CrZolpidem Tartrate | 13 | $8,242 |
| Buprenorphine | 34 | $5,491 |
| Oxycodone Hcl | 130 | $3,745 |
| Morphine Sulfate ErMorphine Sulfate | 154 | $3,545 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 93 | $2,717 |
| Gabapentin | 175 | $2,168 |
| Morphine Sulfate | 47 | $1,687 |
| Lidocaine | 14 | $1,602 |
| Metaxalone | 12 | $1,519 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er | $473 | $44,60767 claims |
| Lilly USA, LLCMounjaro | $216 | $16,01113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 651 physical medicine & rehabilitation providers in Texas.
Other physical medicine & rehabilitation in The Woodlands
- Lawrence NguyenThe Woodlands$4K
- Gerard FranciscoHouston$364K
- Jose UrquidezAustin$332K
- Gireesh ShardaDallas$172K
- Suzanne ManziHouston$143K
- Cindy IvanhoeHouston$111K
- Chad McNeilTyler$64K
- Sheng LiHouston$44K
- Mary RussellShenandoah$37K
- Randall WolcottLubbock$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.